Literature DB >> 7794911

Characterization of a hormone-inducible, high affinity adenosine 3'-5'-cyclic monophosphate phosphodiesterase from the rat Sertoli cell.

M Conti1, S Iona, M Cuomo, J V Swinnen, J Odeh, M E Svoboda.   

Abstract

In previous reports we have shown that FSH and beta-adrenergic agonists regulate the levels of mRNA and increase the activity of a high affinity cAMP phosphodiesterase (cAMP-PDE) in the immature rat Sertoli cell in culture. To identify and characterize the hormone-inducible form(s), the cAMP-PDE activity of the Sertoli cell was partially purified and its properties were determined using biochemical and immunological tools. The cAMP-PDE activity present in the 100,000g supernatant of Sertoli cell extracts was purified more than 2000-fold by four HPLC chromatographic steps. The major purified form of cAMP-PDE had a specific activity of 1-2 mumol/(min.mg of protein). Polyacrylamide gel electrophoresis and silver staining analysis showed that a 67-68 kDa polypeptide comigrated with the major peak of cAMP hydrolytic activity. The molecular weight of the crude or purified enzyme determined by gel filtration and sucrose density gradients was 150,000, suggesting that the native enzyme is an oligomeric structure. This PDE hydrolyzed cAMP with a Km of 1.97 +/- 0.26 microM. The hydrolysis of cAMP was neither inhibited nor stimulated by cGMP concentrations lower than 50 microM. Cyclic nucleotide catalysis required Mg2+, but was insensitive to Ca2+. The activity of this form was competitively inhibited by several inhibitors with the following potency: rolipram > RO 20-1724 > methylisobutylxanthine > cilostamide = milrinone. Because mRNAs derived from two distinct PDE4B and PDE4D genes are present in the Sertoli cell, selective and nonselective PDE antibodies were used to determine the origin of the inducible PDE protein.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7794911     DOI: 10.1021/bi00025a003

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  7 in total

1.  New insights into PDE4B inhibitor selectivity: CoMFA analyses and molecular docking studies.

Authors:  Sara Guariento; Olga Bruno; Paola Fossa; Elena Cichero
Journal:  Mol Divers       Date:  2015-08-20       Impact factor: 2.943

2.  Receptor-mediated stimulation of lipid signalling pathways in CHO cells elicits the rapid transient induction of the PDE1B isoform of Ca2+/calmodulin-stimulated cAMP phosphodiesterase.

Authors:  S Spence; G Rena; M Sullivan; S Erdogan; M D Houslay
Journal:  Biochem J       Date:  1997-01-01       Impact factor: 3.857

3.  Molecular cloning and transient expression in COS7 cells of a novel human PDE4B cAMP-specific phosphodiesterase, HSPDE4B3.

Authors:  E Huston; S Lumb; A Russell; C Catterall; A H Ross; M R Steele; G B Bolger; M J Perry; R J Owens; M D Houslay
Journal:  Biochem J       Date:  1997-12-01       Impact factor: 3.857

4.  Immunohistochemical localisation of PDE5 in Leydig and myoid cells of prepuberal and adult rat testis.

Authors:  Angela Scipioni; Stefania Stefanini; Rocco Santone; Mauro Giorgi
Journal:  Histochem Cell Biol       Date:  2005-11-03       Impact factor: 4.304

5.  Intracellular localization of the PDE4A cAMP-specific phosphodiesterase splice variant RD1 (RNPDE4A1A) in stably transfected human thyroid carcinoma FTC cell lines.

Authors:  L Pooley; Y Shakur; G Rena; M D Houslay
Journal:  Biochem J       Date:  1997-01-01       Impact factor: 3.857

6.  cAMP-specific phosphodiesterase HSPDE4D3 mutants which mimic activation and changes in rolipram inhibition triggered by protein kinase A phosphorylation of Ser-54: generation of a molecular model.

Authors:  R Hoffmann; I R Wilkinson; J F McCallum; P Engels; M D Houslay
Journal:  Biochem J       Date:  1998-07-01       Impact factor: 3.857

7.  Further Insights in the Binding Mode of Selective Inhibitors to Human PDE4D Enzyme Combining Docking and Molecular Dynamics.

Authors:  Pasqualina D'Ursi; Sara Guariento; Gabriele Trombetti; Alessandro Orro; Elena Cichero; Luciano Milanesi; Paola Fossa; Olga Bruno
Journal:  Mol Inform       Date:  2016-06-20       Impact factor: 3.353

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.